Cargando…

Preventing antimalarial drug resistance with triple artemisinin-based combination therapies

Increasing levels of artemisinin and partner drug resistance threaten malaria control and elimination globally. Triple artemisinin-based combination therapies (TACTs) which combine artemisinin derivatives with two partner drugs are efficacious and well tolerated in clinical trials, including in area...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Tran Dang, Gao, Bo, Amaratunga, Chanaki, Dhorda, Mehul, Tran, Thu Nguyen-Anh, White, Nicholas J., Dondorp, Arjen M., Boni, Maciej F., Aguas, Ricardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387089/ https://www.ncbi.nlm.nih.gov/pubmed/37516752 http://dx.doi.org/10.1038/s41467-023-39914-3

Ejemplares similares

Artemisinin and multidrug-resistant Plasmodium falciparum – a threat for malaria control and elimination
por: Dhorda, Mehul, et al.
Publicado: (2021)

Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations
por: Tindana, Paulina, et al.
Publicado: (2021)

To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?
por: de Haan, Freek, et al.
Publicado: (2021)

Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives
por: O’Flaherty, Katherine, et al.
Publicado: (2019)

Pre-existing partner-drug resistance to artemisinin combination therapies facilitates the emergence and spread of artemisinin resistance: a consensus modelling study
por: Watson, Oliver J, et al.
Publicado: (2022)

Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
por: Tindana, Paulina, et al.
Publicado: (2022)

Expert perspectives on the introduction of Triple Artemisinin-based Combination Therapies (TACTs) in Southeast Asia: a Delphi study
por: de Haan, Freek, et al.
Publicado: (2022)

Antimalarial mass drug administration in large populations and the evolution of drug resistance
por: Nguyen, Tran Dang, et al.
Publicado: (2023)

Exploring the feasibility of introducing triple artemisinin-based combination therapy in the malaria treatment policy in Vietnam
por: Cao, Van Anh Thi, et al.
Publicado: (2023)

Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion
por: de Haan, Freek, et al.
Publicado: (2023)

Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.
por: Tindana, Paulina, et al.
Publicado: (2021)

The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso
por: Guissou, Rosemonde M., et al.
Publicado: (2023)

Optimum population-level use of artemisinin combination therapies: a modelling study
por: Nguyen, Tran Dang, et al.
Publicado: (2015)

Artemisinin resistance without pfkelch13 mutations in Plasmodium falciparum isolates from Cambodia
por: Mukherjee, Angana, et al.
Publicado: (2017)

Modeling policy interventions for slowing the spread of artemisinin-resistant pfkelch R561H mutations in Rwanda
por: Zupko, Robert J., et al.
Publicado: (2023)

Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial
por: Peto, Thomas J, et al.
Publicado: (2022)

Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso
por: Zupko, Robert J., et al.
Publicado: (2022)

Artemisinin Resistance and Stage Dependency of Parasite Clearance in Falciparum Malaria
por: Intharabut, Benjamas, et al.
Publicado: (2019)

The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia
por: Maude, Richard J, et al.
Publicado: (2009)

Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response
por: Zhu, Lei, et al.
Publicado: (2022)

Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?
por: van der Pluijm, Rob W, et al.
Publicado: (2022)

Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia
por: Cutts, Julia C, et al.
Publicado: (2022)

A framework for stakeholder engagement in the adoption of new anti-malarial treatments in Africa: a case study of Nigeria
por: Mokuolu, Olugbenga Ayodeji, et al.
Publicado: (2023)

Probability of emergence of antimalarial resistance in different stages of the parasite life cycle
por: Pongtavornpinyo, Wirichada, et al.
Publicado: (2009)

Transmission of Artemisinin-Resistant Malaria Parasites to Mosquitoes under Antimalarial Drug Pressure
por: Witmer, Kathrin, et al.
Publicado: (2020)

Artemisinin Antimalarials: Preserving the “Magic Bullet”
por: Maude, Richard J, et al.
Publicado: (2010)

Counterfeit artesunate antimalarials in southeast Asia
por: Newton, Paul N, et al.
Publicado: (2003)

Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
por: van der Pluijm, Rob W, et al.
Publicado: (2020)

Clinical needs assessment to inform development of a new assay to detect antimalarial drugs in patient samples: A case study
por: Coonahan, Erin S., et al.
Publicado: (2023)

Cooperation in Countering Artemisinin Resistance in Africa: Learning from COVID-19
por: Rosenthal, Philip J., et al.
Publicado: (2022)

Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study
por: Tun, Kyaw Myo, et al.
Publicado: (2016)

Towards malaria elimination in Savannakhet, Lao PDR: mathematical modelling driven strategy design
por: Tun, Sai Thein Than, et al.
Publicado: (2017)

DNA binding by the antimalarial compound artemisinin
por: Slavkovic, Sladjana, et al.
Publicado: (2022)

Effectiveness and safety of 3 and 5 day courses of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar
por: Tun, Kyaw Myo, et al.
Publicado: (2018)

The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study
por: Imwong, Mallika, et al.
Publicado: (2017)

Artemisinin resistance – modelling the potential human and economic costs
por: Lubell, Yoel, et al.
Publicado: (2014)

Split dosing of artemisinins does not improve antimalarial therapeutic efficacy
por: White, N. J., et al.
Publicado: (2017)

Measuring the Association between Artemisinin-Based Case Management and Malaria Incidence in Southern Vietnam, 1991–2010
por: Peak, Corey M., et al.
Publicado: (2015)

Plasmepsin II–III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum
por: Bopp, Selina, et al.
Publicado: (2018)

Role of Seasonal Importation and Random Genetic Drift on Selection for Drug-Resistant Genotypes of Plasmodium falciparum in High Transmission Settings
por: Zupko, Robert J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h89harvuhamlnbc6urtr2mmmm4